Fetal therapy for Down syndrome: an ethical exploration

Guido de Wert, Wybo Dondorp*, Diana W. Bianchi

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Web of Science)
149 Downloads (Pure)

Abstract

Background Parallel to recent advances in prenatal screening for Down syndrome (DS), therapies for different aspects of the condition have become available. As intellectual disability is a key aspect, this is an active area for research. Several groups have hypothesized that prenatal interventions will give better chances at improving cognitive functioning in persons with DS than postnatal treatment. Clinical trials are being developed.

Method We first discuss the ethical pros and cons of trying to improve cognitive functioning in persons with DS to see if there are categorical objections to the general idea, and then move on to explore ethically relevant aspects of the prospect of developing fetal therapy for DS (FTDS).

Results Only on the basis of a one-dimensional emphasis on the social model of disability would (fetal) therapy aimed at cognitive improvement be inherently problematic.

Conclusions Inviting pregnant women to participate in FTDS-research should be based on adequate pre-clinical trials, as well as information aimed at avoiding the so-called 'therapeutic misconception'. Should FTDS be proven to be effective and safe, women carrying a fetus with trisomy 21 who have decided to continue the pregnancy may have a moral obligation to make use of this option. (C) 2016 John Wiley & Sons, Ltd.

Original languageEnglish
Pages (from-to)222-228
Number of pages7
JournalPrenatal Diagnosis
Volume37
Issue number3
DOIs
Publication statusPublished - Mar 2017

Keywords

  • CELL-FREE DNA
  • PRENATAL-DIAGNOSIS
  • ANEUPLOIDY
  • DISABILITY
  • CHALLENGES
  • FETUSES

Cite this